The Helix Protocol: Why SS-31 and NAD+ Work Better Together

If you have been researching peptide therapy and longevity for any length of time, you have likely encountered both SS-31 and NAD+. They come up in the same conversations, on the same forums, and in the same protocols. There is a reason for that. These two compounds are doing something genuinely complementary inside your cells, and the research behind combining them is starting to show what that actually means in practice.

This article is about how they work, why they work better together, and what that looks like as a physician-guided treatment protocol.

Why Mitochondria Are at the Center of How We Age

To understand why SS-31 and NAD+ matter, it helps to start with the mitochondria. You have likely heard them described as the "powerhouses of the cell," which is accurate but undersells the point. Mitochondria are not just energy factories -- they are also central to how your cells signal, repair themselves, and decide whether to keep functioning or start declining.

As we age, our mitochondria become less efficient. They produce less energy, generate more cellular waste in the form of damaging byproducts called reactive oxygen species (essentially chemical exhaust that damages nearby structures), and begin to lose the organized internal architecture that allows them to work properly. This decline shows up in ways most people recognize: lower energy levels, slower recovery, changes in body composition, and a general sense that the body is not bouncing back the way it once did.

This is not a metaphor. It is a measurable biological process, and it is one of the better-documented mechanisms underlying why we feel older as we get older. The question researchers have been asking is whether it can be slowed or, in some cases, partially reversed. SS-31 and NAD+ are two of the most compelling tools emerging from that line of inquiry.

What SS-31 Does (and Why Its Mechanism Is Unusual)

SS-31, also known as elamipretide and sold under the pharmaceutical name Forzinity, is a short peptide -- a small chain of amino acids -- that targets a specific problem inside aging mitochondria. Unlike most compounds that work by flooding the body with antioxidants, SS-31 addresses a structural issue at the source.

Inside each mitochondrion, there is an inner membrane where the actual work of energy production takes place. This membrane contains a molecule called cardiolipin, which acts as a scaffold, holding the energy-producing complexes in the precise spatial arrangement they need to function efficiently. Think of cardiolipin as the framework that keeps everything in the right place.

As we age, cardiolipin degrades. When it does, the architecture of the inner membrane begins to collapse. Energy production drops. More damaging byproducts are generated. The mitochondrion becomes less of a precision engine and more of an inefficient, leaking one.

SS-31 binds to cardiolipin and shields it from this age-related damage. It does not just neutralize waste after it is produced -- it protects the structure that keeps the engine running cleanly in the first place. Preclinical research in aged animals has shown meaningful improvements in ATP production (the actual chemical form energy takes in the body), reductions in oxidative damage, and improvements in function across multiple tissues including cardiac muscle, kidney cells, and brain vasculature.

In September 2025, SS-31 became the first mitochondria-targeted therapeutic to receive FDA approval, cleared for a rare genetic condition called Barth syndrome that involves exactly the kind of cardiolipin dysfunction SS-31 addresses. That approval does not extend to off-label longevity use, but the underlying mechanism that earned it is the same one that makes SS-31 relevant to aging more broadly.

What NAD+ Does (and Why It Is Not the Same Thing)

NAD+, which stands for nicotinamide adenine dinucleotide, is a molecule your body already makes and uses constantly. It functions as a kind of currency for cellular energy -- the medium through which your cells convert food into usable fuel. NAD+ also activates a class of proteins called sirtuins (think of them as the body's maintenance crew), which are responsible for repairing DNA, regulating inflammation, and managing a wide range of processes associated with healthy aging.

Here is the problem: NAD+ levels decline with age. By the time most people are in their 40s and 50s, their cellular NAD+ levels may be significantly lower than they were in their 20s. When NAD+ falls, the entire downstream cascade it supports -- energy production, DNA repair, inflammatory regulation -- becomes less effective.

This is where NAD+ therapy comes in. Rather than injecting NAD+ directly (which the body cannot absorb efficiently through most routes), AIRA's protocols use compounds that the body readily converts into NAD+ once absorbed. The result is a restoration of that cofactor supply, essentially giving the mitochondria the fuel and signaling molecules they need to run properly.

Why the Combination Produces Something Neither Alone Can

Here is where the research becomes genuinely interesting. SS-31 and NAD+ are addressing the same underlying problem -- aging mitochondria -- but through entirely different mechanisms.

SS-31 is a structural repair. It protects the physical scaffold of the mitochondrion, keeping the inner membrane organized and the energy-production complexes properly positioned. NAD+ is a fuel and signaling restoration. It replenishes the molecular currency the mitochondria need to actually run those complexes once they are in place.

A useful analogy: imagine an engine that has been running poorly. SS-31 is the mechanic who rebuilds the parts and gets everything aligned. NAD+ is the high-quality fuel that allows the rebuilt engine to perform. Neither is a complete solution on its own -- a well-maintained engine with no fuel goes nowhere, and premium fuel cannot compensate for a structurally compromised engine.

This is not just a conceptual argument. A study published in the journal Aging Cell tested SS-31 and NMN (a NAD+ precursor, meaning a compound the body converts into NAD+) individually and in combination in aged mouse hearts. SS-31 alone partially reversed age-related decline in one measure of cardiac function. NMN alone fully reversed a different measure. The combined treatment produced results that best recapitulated what a young heart looks like -- improving both dimensions more effectively than either compound achieved independently. The researchers described it as a synergistic effect, meaning the total outcome was greater than the sum of the parts.

This kind of finding is what drives the thinking behind AIRA's Helix Protocol. Physician-guided combination therapy is not about stacking compounds arbitrarily. It is about identifying the different functional bottlenecks that limit how well aging mitochondria perform, and addressing each one in a way that the others cannot.

What This Protocol Looks Like in Practice

AIRA's Helix Protocol pairs SS-31 and NAD+ as a combined offering because the two compounds address different aspects of the same underlying problem. How a physician structures the protocol for any individual patient will depend on their labs, health history, and goals.

What many patients find, under physician supervision, is that NAD+ runs as a continuous daily foundation while SS-31 is cycled in deliberate phases -- commonly 8 to 12 weeks on, followed by a break -- with the physician using that pause to assess how well the improvements are holding before determining whether another cycle is warranted.

Most patients begin noticing changes in energy and recovery within four to six weeks. Because these compounds are working at the cellular level rather than producing surface-level stimulant effects, improvements tend to feel qualitative at first before becoming more measurable over subsequent months. Your AIRA physician will determine the specific timing, dosing, and cycle structure that makes sense for your biology.

A Note on Evidence and Realistic Expectations

Most of the research supporting SS-31 and NAD+ therapy is preclinical, meaning it has been conducted in animal models rather than large-scale human trials. The Aging Cell cardiac study referenced above is representative of the quality and direction of that research, but it is important to be honest that this is not the same as the evidence base supporting FDA-approved medications. The human experience data is emerging and directionally consistent with what the animal research predicts, but patients should approach this with appropriate calibration.

What the existing evidence does support clearly is the underlying mechanism: aging mitochondria have two distinct functional problems (structural degradation and substrate depletion), SS-31 addresses one and NAD+ addresses the other, and combining them appears to produce better outcomes than either alone. For anyone serious about longevity from a cellular standpoint, that is a compelling foundation.

The Case for Physician Guidance Here

Mitochondrial protocols are not the place for self-directed supplementation. SS-31 is a prescription peptide available only through licensed providers. The dosing, timing, and combination logic matter, and getting them right requires someone who understands both the science and your individual health picture.

AIRA's physicians are familiar with the research behind mitochondrial-targeted protocols and work with each patient to build a regimen that makes sense for their goals, their biology, and the current state of the evidence. If you are curious whether the Helix Protocol is appropriate for you, the best starting point is AIRA's intake process.